ARCHIVES

European regulators plan more rigorous rules for accelerated approval in cancer.

This article is from The Cancer Letter archive.

Vol. 31 No. 41 | November 11, 2005

Download PDF Visit The Full Archive

Related Articles

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

December 10, 2004

Oxaliplatin Regimens Extend Survival Of Advanced Colorectal Cancer, Study Finds

June 27, 2003

In Brief: Levine Leaves NIH For Pittsburgh; Fischbach Leaves Harvard For NIH; NCI Researcher Dies

June 12, 1998

Cancer Advocates Use Benefit Analysis To Press For Funds

May 11, 1990

NIH Should Review CRADA Pricing, Wyden Write to Shalala

February 5, 1993

In Brief: Susan Braun Named CEO, Komen Foundation; NCCF Research Fellowship Honors Norman

July 12, 1996